0001765581-23-000036.txt : 20230310
0001765581-23-000036.hdr.sgml : 20230310
20230310181038
ACCESSION NUMBER: 0001765581-23-000036
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230308
FILED AS OF DATE: 20230310
DATE AS OF CHANGE: 20230310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sablich Kim
CENTRAL INDEX KEY: 0001758790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33500
FILM NUMBER: 23725132
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 2000 SIERRA POINT PARKWAY
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc
CENTRAL INDEX KEY: 0001232524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981032470
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 353-1-634-7800
MAIL ADDRESS:
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030513
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2023-03-08
0
0001232524
Jazz Pharmaceuticals plc
JAZZ
0001758790
Sablich Kim
5TH FL, WATERLOO EXCHANGE
WATERLOO RD
DUBLIN 4
L2
IRELAND
0
1
0
0
EVP, GM of U.S., Commercial Ma
Ordinary Shares
2023-03-08
4
S
0
1752
139.42
D
31821
D
Ordinary Shares
2023-03-08
4
S
0
1261
140.19
D
30560
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
By: Adam Guttman, as attorney in fact For: Kimbely Sablich
2023-03-10